0000912282-23-000133.txt : 20230615
0000912282-23-000133.hdr.sgml : 20230615
20230615135253
ACCESSION NUMBER: 0000912282-23-000133
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20230614
FILED AS OF DATE: 20230615
DATE AS OF CHANGE: 20230615
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Disbrow Joshua R.
CENTRAL INDEX KEY: 0001566240
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-38247
FILM NUMBER: 231016900
MAIL ADDRESS:
STREET 1: AMPIO PHARMACEUTICALS, INC.
STREET 2: 5445 DTC PARKWAY, SUITE 925
CITY: GREENWOOD VILLAGE
STATE: CO
ZIP: 80111
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: AYTU BIOPHARMA, INC
CENTRAL INDEX KEY: 0001385818
STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834]
IRS NUMBER: 470883144
STATE OF INCORPORATION: DE
FISCAL YEAR END: 0630
BUSINESS ADDRESS:
STREET 1: 373 INVERNESS PARKWAY
STREET 2: SUITE 206
CITY: ENGLEWOOD
STATE: CO
ZIP: 80112
BUSINESS PHONE: (720) 437-6580
MAIL ADDRESS:
STREET 1: 373 INVERNESS PARKWAY
STREET 2: SUITE 206
CITY: ENGLEWOOD
STATE: CO
ZIP: 80112
FORMER COMPANY:
FORMER CONFORMED NAME: AYTU BIOSCIENCE, INC
DATE OF NAME CHANGE: 20150609
FORMER COMPANY:
FORMER CONFORMED NAME: AYTU BIOSCIENCE, INC.
DATE OF NAME CHANGE: 20150609
FORMER COMPANY:
FORMER CONFORMED NAME: Rosewind CORP
DATE OF NAME CHANGE: 20070110
4
1
form4.xml
X0407
4
2023-06-14
0001385818
AYTU BIOPHARMA, INC
AYTU
0001566240
Disbrow Joshua R.
C/O AYTU BIOPHARMA, INC.
373 INVERNESS PARKWAY, SUITE 206
ENGLEWOOD
CO
80112
true
true
Chief Executive Officer
false
Common Shares
2023-06-14
4
P
0
14000
1.8628
A
71591
D
The purchase price reported in Column 4 above is an average weighted price. These shares were purchased in multiple transactions at prices ranging from $1.79 to $1.87, inclusive. The reporting person undertakes to provide to AYTU Biopharma, Inc., any security holder of AYTU Biopharma, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth in this footnote.
Reflects a 1:20 reverse stock split effected by the Issuer on January 4, 2023.
/s/ Mark Oki as attorney-in-fact for Joshua R. Disbrow
2023-06-15